Background: Kidneys are involved in tryptophan (TRP) metabolism in two ways. They eliminate TRP derivatives on the one hand, and they produce several enzymes taking part in TRP metabolism mainly via the kynurenine pathway on the other. The aim of the present study was to examine the time-course of changes in the peripheral kynurenine products degradation during experimental chronic renal failure in rats. Methods: Tryptophan, kynurenine, 3-hydroxykynurenine, kynurenic acid, xanthurenic acid, anthranilic acid and quinolinic acid were determined in plasma using high-performance liquid chromatography technique with UV, fluorescence and electrochemical detection. Results: A decreased TRP level and significant increase in kynurenine pathway metabolite concentrations in plasma of uremic rats were found. Conclusions: Substantial disturbances in the peripheral kynurenic pathway were observed in experimental chronic renal failure. They may contribute to several symptoms of uremia.

Keywords:
Tryptophan, Kynurenine, 3-Hydroxykynurenine, Kynurenic acid, Xathurenic acid, Anthranilic acid, Quinolinic acid, Renal failure
1.
Stone TW: Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993;45:309–379.
2.
Moroni F: Tryptophan metabolism and brain function: Focus on kynurenine and other indole metabolites. Eur J Pharm 1999;375:887–100.
3.
Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D: Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol 1999;467:133–138.
4.
Bertazzo A, Punzi L, Bertazzolo N, Pianon M, Pozzuoli A, Costa CV, Allegri G: Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines. Adv Exp Med Biol 1999;467:565–570.
5.
Sakai N, Saito K, Kaufman S, Heyes MP, Milstien S: Induction of pterin synthesis is not required for cytokine-stimulated tryptophan metabolism. Biochem J 1993;295:543–547.
6.
Saito K, Heyes MP: Kynurenine pathway enzymes in brain. Rec Adv Tryp Res 1996;75:485–492.
7.
Mawal MR, Deshmukh DR: Purification and properties of kynurenine aminotransferase from rat kidney. Biochem J 1991;279:595–599.
8.
Buchi R, Alberati-Gani D, Malherbe P, Kohler C, Broger C, Cesura AM: Cloning and functional expression of a soluble form of kynurenine/α-aminoadipate aminotransferase from rat kidney. J Biol Chem 1995;270:29330–29335.
9.
Holmes EW: Determination of serum kynurenine and hepatic tryptophan dioxygenase activity by high liquid chromatography. Anal Biochem 1988;172:518–525.
10.
Mason M: Effects of calcium ions and quinolinic acid on rat kidney mitochondrial kynurenine aminotransferase. Biochem Biophys Res Commun 1974;60:64–69.
11.
Holmes EW, Kahan SE: Tryptophan distribution and metabolism in experimental chronic renal insufficiency. Exp Mol Pathol 1987;46:89–101.
12.
Holmes EW, Russel PM, Kinzler GJ, Reckard CR, Flanigan RC, Thompson KD, Bermes EW: Oxidative tryptophan metabolism in renal allograft recipients: Increased kynurenine synthesis is associated with inflammation and OKT3 therapy. Cytokine 1992;4:205–213.
13.
Saito K, Heyes MP: Kynurenine pathway enzymes in brain-properties of enzymes and regulation of quinolinic acid synthesis. Adv Exp Med Biol 1996;398:485–492.
14.
Kawashima Y, Sanaka T, Sugino N, Takashashi M, Mizoguchi H: Supressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia. Adv Exp Med Biol 1987;223:69–72.
15.
Ormrod D, Miller T: Experimental uremia. Nephron 1980;26:249–254.
16.
Heyes MP: Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection. J Chromatogr 1988;428:340–344.
17.
Herve C, Beyne H, Jamault H, Delacoux E: Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorometric detection. J Chromatogr 1996;675:157–161.
18.
Werner-Felmayer G, Werner E, Fuchs D, Hausen A, Reibnegger G, Wachter H: Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta 1989;1012:140–147.
19.
Thomas SR, Stocker R: Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999;4:199–220.
20.
Taylor MW, Feng G: Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516–2522.
21.
Halonen SK, Chiu FC, Weiss LM: Effect of cytokines on growth of Toxoplasma gondii in murine astrocytes. Infect Immunity 1998;66:4989–4993.
22.
MacKenzie CR, Langen R, Takikawa O, Daubener W: Inhibition of indoleamine 2,3-dioxygenase in human macrophages inhibits interferon-gamma-induced bacteriostasis but does not abrogate toxoplasmastasis. Eur J Immunol 1999;29:3254–3261.
23.
Hissong BD, Carlin JM: Potentation of interferon-induced indoleamine 2,3-dioxygenase mRNA in human mononuclear phagocytes by lipopolysaccharide and interleukin-1. J Interferon Cytokine Res 1997;17:387–393.
24.
Rudzite V, Sileniece G, Liepina D, Dalmana A, Zirne R: Impairment of kynurenine metabolism in cardiovascular disease; in Schwarcz R (ed): Kynurenine and Serotonin Pathways. New York, Plenum Press, 1991, pp 663–667.
25.
Takeuchi F, Tsubouchi R, Izuta S, Shibata Y: Kynurenine metabolism and xanthurenic acid formation in vitamin B6-deficient rat after tryptophan injection. J Nutr Sci Vitaminol 1989;35:111–122.
26.
Okuda S, Nishiyama N, Saito H, Katsuki H: Hydrogen peroxide-mediated neuronal cell death induced by endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci USA 1996;93:12553–12558.
27.
Lou GL, Pinsky C, Sitar DS: Kynurenic acid distribution into brain and peripherial tissues of mice. Can J Physiol Pharmacol 1994;72:161–167.
28.
Hodgkins PS, Wu H-Q, Zielke HR, Schwarcz R: 2-Oxoacids regulate kynurenic acid production in the rat brain: Studies in vitro and in vivo. J Neurochem 1999;72:643–651.
29.
Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP: Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 1996;320:595–597.
30.
Blight AR, Cohen TI, Saito K, Heyes MP: Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. Brain 1995;118:735–752.
31.
Niwa T, Yoshizumi H, Emoto Y, Miyazaki T, Hashimoto N, Takeda N, Tatematsu A, Maeda K: Accumulation of quinolinic acid in uremic serum and its removal by hemodialysis. Clin Chem 1991;37:159–161.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.